Suppr超能文献

[哮喘的吸入皮质激素治疗:何时开始及如何停药?]

[Inhaled corticotherapy in asthma: when should it be started and how to stop?].

作者信息

Aubier M

机构信息

Service de Pneumologie, INSERM U408, Paris.

出版信息

Rev Pneumol Clin. 1996;52(2):145-9.

PMID:8761645
Abstract

Bronchial inflammation is an almost constantly encountered feature in asthma, even in early stages. Corticosteroid therapy has been shown to be effective both in reducing bronchial inflammation and improving signs of bronchial hyperreactivity. The possible side effects of prolonged inhaled corticosteroids cannot be ignored. Thus, while the indication for inhaled corticosteroids is severe asthma is clear, many questions are raised in case of intermittent minor asthma. There is still much debate over the correct initial dose (high or low) and the clinical and functional criteria for dose reduction or withdrawal. We discuss here the modalities for starting and stopping inhaled corticosteroids in patients with asthma.

摘要

支气管炎症几乎是哮喘中始终存在的特征,即使在早期阶段也是如此。皮质类固醇疗法已被证明在减轻支气管炎症和改善支气管高反应性体征方面均有效。长期吸入皮质类固醇的潜在副作用不容忽视。因此,虽然吸入皮质类固醇用于重度哮喘的指征很明确,但对于间歇性轻度哮喘则引发了许多问题。关于正确的初始剂量(高剂量或低剂量)以及减量或停药的临床和功能标准仍存在诸多争议。我们在此讨论哮喘患者开始和停用吸入皮质类固醇的方式。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验